FLT3 and acute myeloid leukemia: The combination of sorafenib, plerixafor (a SDF-1/CXCR4 inhibitor), and G-CSF to increase mobilization and elimination of FLT3-ITD progenitor cells was conducted in a phase I trial, and 28 patients with R/R FLT3-ITD-mutated AML were enrolled, showing an ORR of 37% [30].